Nucleic acid sensing pathways in kidney disease development
Study limitation reported by the research below: “The 'practice changing' impact flag reflects the breadth of emerging therapeutic targets reviewed, not a single pivotal trial result — most agents remain preclinical or in early-phase trials.”